Does low-dose interleukin-2 immunotherapy improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission : Cancer and Leukemia Group B Study 9720?
Low-dose rIL-2 maintenance immunotherapy is not a successful strategy in older AML patients.
The data suggest that in vivo, moderate concentrations of bile acids increase colonic permeability in rats via a mechanism that is inhibited by NO in distal but not in proximal colon. In distal colon, NO may contribute to the maintenance of epithelial barrier function.